PortalPublikationenEffect of oral cholestyramine on the elimination of high-dos...

Effect of oral cholestyramine on the elimination of high-dose methotrexate.

Standard

Effect of oral cholestyramine on the elimination of high-dose methotrexate. / Erttmann, Rudolf; Landbeck, G.

in: J CANCER RES CLIN, Jahrgang 110, Nr. 1, 1, 1985, S. 48-50.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Erttmann, R & Landbeck, G 1985, 'Effect of oral cholestyramine on the elimination of high-dose methotrexate.', J CANCER RES CLIN, Jg. 110, Nr. 1, 1, S. 48-50. <http://www.ncbi.nlm.nih.gov/pubmed/4019569?dopt=Citation>

APA

Erttmann, R., & Landbeck, G. (1985). Effect of oral cholestyramine on the elimination of high-dose methotrexate. J CANCER RES CLIN, 110(1), 48-50. [1]. http://www.ncbi.nlm.nih.gov/pubmed/4019569?dopt=Citation

Vancouver

Erttmann R, Landbeck G. Effect of oral cholestyramine on the elimination of high-dose methotrexate. J CANCER RES CLIN. 1985;110(1):48-50. 1.

Bibtex

@article{a6200092446d4e79943b7d15ca66fb9c,
title = "Effect of oral cholestyramine on the elimination of high-dose methotrexate.",
abstract = "The anion exchange resin cholestyramine binds methotrexate (MTX) effectively in vitro. The binding capacity exceeds that of activated charcoal by a factor of 5.4. On two patients undergoing high-dose MTX therapy it is also shown that cholestyramine binds MTX in vivo. This leads to an enhanced non-renal excretion of MTX. Therefore, cholestyramine may be of clinical value in patients who develop renal function impairment whilst undergoing MTX therapy.",
author = "Rudolf Erttmann and G Landbeck",
year = "1985",
language = "Deutsch",
volume = "110",
pages = "48--50",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Effect of oral cholestyramine on the elimination of high-dose methotrexate.

AU - Erttmann, Rudolf

AU - Landbeck, G

PY - 1985

Y1 - 1985

N2 - The anion exchange resin cholestyramine binds methotrexate (MTX) effectively in vitro. The binding capacity exceeds that of activated charcoal by a factor of 5.4. On two patients undergoing high-dose MTX therapy it is also shown that cholestyramine binds MTX in vivo. This leads to an enhanced non-renal excretion of MTX. Therefore, cholestyramine may be of clinical value in patients who develop renal function impairment whilst undergoing MTX therapy.

AB - The anion exchange resin cholestyramine binds methotrexate (MTX) effectively in vitro. The binding capacity exceeds that of activated charcoal by a factor of 5.4. On two patients undergoing high-dose MTX therapy it is also shown that cholestyramine binds MTX in vivo. This leads to an enhanced non-renal excretion of MTX. Therefore, cholestyramine may be of clinical value in patients who develop renal function impairment whilst undergoing MTX therapy.

M3 - SCORING: Zeitschriftenaufsatz

VL - 110

SP - 48

EP - 50

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 1

M1 - 1

ER -